Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

MS at the Limits 2022

19–20 September 2022 | London, UK

MS at the Limits 2022

19–20 September 2022 | London, UK
Current understanding of MS genetics and diversity 1:32
Current understanding of MS genetics and diversity
Benjamin Jacobs • 22 Sep 2022
Is MS susceptibility influenced by genetic risk factors? 3:13
Is MS susceptibility influenced by genetic risk factors?
Sergio Baranzini • 27 Sep 2022
Octopus – inside the progressive MS mega-trial 4:51
Octopus – inside the progressive MS mega-trial
Jeremy Chataway • 27 Sep 2022
DMT management – where disease biology and treatment algorithms meet 1:26
DMT management – where disease biology and treatment algorithms meet
Emma Tallantyre • 23 Sep 2022
When should DMTs be stopped when treating MS? 2:11
When should DMTs be stopped when treating MS?
Emma Tallantyre • 23 Sep 2022
How will Octopus affect the treatment of progressive MS? 4:43
How will Octopus affect the treatment of progressive MS?
Jeremy Chataway • 27 Sep 2022
Challenges in including ethnic diversity in MS genetic studies 1:06
Challenges in including ethnic diversity in MS genetic studies
Benjamin Jacobs • 22 Sep 2022
Future of genetics in MS: understanding disease progression 2:02
Future of genetics in MS: understanding disease progression
Sergio Baranzini • 27 Sep 2022
Progressive MS: discovering the new and repurposing the old 2:05
Progressive MS: discovering the new and repurposing the old
Emma Tallantyre • 23 Sep 2022
Benefits of studying MS genetics in ancestrally diverse populations 1:39
Benefits of studying MS genetics in ancestrally diverse populations
Benjamin Jacobs • 22 Sep 2022
UK guidance on MS and the risk of infection 1:57
UK guidance on MS and the risk of infection
Emma Tallantyre • 23 Sep 2022
The role of the gut microbiota in MS 4:18
The role of the gut microbiota in MS
Sergio Baranzini • 27 Sep 2022
Long-term treatment with anti-CD20 mAbs – is it feasible? 2:50
Long-term treatment with anti-CD20 mAbs – is it feasible?
Emma Tallantyre • 23 Sep 2022
Driving progress in progressive MS with multi-arm trials 1:25
Driving progress in progressive MS with multi-arm trials
Jeremy Chataway • 27 Sep 2022
How do environmental risk factors interact with genetics in MS? 3:24
How do environmental risk factors interact with genetics in MS?
Sergio Baranzini • 27 Sep 2022
The ADAMS study: MS genetics in under-represented populations 2:08
The ADAMS study: MS genetics in under-represented populations
Benjamin Jacobs • 22 Sep 2022
The content of VJNeurology is intended for healthcare professionals